The results of the OlympiA clinical trial, involving ICR researchers, shows giving the drug olaparib for one year to breast cancer patients with inherited BRCA mutations, after they have completed initial treatment, reduced the chance of their breast cancer returning.

Professor Andrew Tutt, Head of Breast Cancer Research at the ICR, explains more.

свернуть